|
|
|
| home > epc > autumn 2002 > the 38th annual meeting of the drug information association, chicago |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
The Drug Information Association (DIA) held its 38th Annual Meeting in June. It was attended by about 7,000 delegates and included a large exhibition with approximately 475 exhibitors. The scale of the meeting, with sessions covering 29 interest areas, often made it difficult to choose which session to attend, so this report refers to those that I did attend, with apologies to all the others that I missed.
The first session included views from three business analysts on the CRO market. The overall trend is a return to financial stability and health within the market, exemplified by the (then) potential IPO of Inveresk. The CRO market was projected as US$9.3 billion for 2003, with the greatest increase expected in Phase II and IV clinical trials.
A recurring theme from all of the analysts was the importance of quality of service as a success factor for CROs. The relationship between the pharmaceutical sponsor and the CRO is often tested, as clinical research services are frequently purchased as a commodity, thereby removing the capacity to develop trust between the two parties. One speaker suggested that the length of the contracts used in these transactions is indicative of the lack of trust in the relationship.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
DIA Annual EuroMeeting
26-28 March 2012, Copenhagen, Denmark
The EuroMeeting attracts more than 3,000 professionals from over 50 countries. It brings together professionals from the biopharmaceutical industry, contract service organisations, clinical research, regulatory agencies, health ministries, patients’ organisations and universities. This convergence affords attendees the opportunity to network with professional colleagues from around the world.
More info >> |
|
 |
News and Press Releases |
 |
Greenphire and Merge Healthcare Form Exclusive Partnership to Integrate Clinical Payment and EDC Platforms
Greenphire announced today that it has
formed an exclusive strategic partnership with the clinical trials division of
Merge Healthcare (NASDAQ: MRGE), a leading provider of clinical
trial solutions, to offer integrated functionality between Merge’s EDC
technology and Greenphire’s eClinicalGPS site and vendor payment management
technology.
More info >> |
|
|
